CV Sciences, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

NET LOSS PER SHARE

NET LOSS PER SHARE

9 Months Ended

Sep. 30, 2020

The Company computes basic net loss per share using the weighted-average number of common shares outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the weighted-average number of common shares plus potential common shares. The Company's stock options, including those with performance conditions, are included in the calculation of diluted net loss per share using the treasury stock method when their effect is dilutive. Potential common shares are excluded from the calculation of diluted net loss per share when their effect is anti-dilutive.

The following common stock equivalents were not included in the calculation of net loss per diluted share because their effect were anti-dilutive (in thousands):


	Three months ended September 30,		Nine months ended September 30,
	2020	2019	2020	2019
Stock options	21,155	18,640	21,155	18,640
Performance stock options	5,000	7,250	5,000	7,250
Total	26,155	25,890	26,155	25,890

The above table excludes 8,000,000 unvested performance stock options for the three and nine months ended September 30, 2020 and 10,750,000 unvested performance stock options for the three and nine months ended September 30, 2019, which vest upon the completion of future performance conditions.